Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 5/20 | 0.54 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622030 | 1.00 | CHEK2 (0.54) | CHEK2SMAD3MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL4013873 | 0.99 | CHEK2 (0.53) | CHEK2SMAD3MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL4013885 | 0.99 | CHEK2 (0.53) | CHEK2SMAD3MEN1KMT2AALDH1A1 | |
| SCHEMBL1084926 | 0.93 | CHEK2 (0.54) | CHEK2SMAD3MEN1KMT2AOPRM1 | |
| SCHEMBL12721471 | 0.92 | CHEK2 (0.51) | CHEK2SMAD3MEN1KMT2AALDH1A1 | |
| SCHEMBL1624231 | 0.92 | CHEK2 (0.51) | CHEK2SMAD3MEN1KMT2AALDH1A1 | |
| SCHEMBL1624229 | 0.92 | CHEK2 (0.51) | CHEK2SMAD3MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL1624456 | 0.91 | CHEK2 (0.51) | CHEK2SMAD3MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL1624453 | 0.91 | CHEK2 (0.51) | CHEK2SMAD3MEN1KMT2AALDH1A1 | |
| SCHEMBL1084793 | 0.91 | CHEK2 (0.51) | CHEK2SMAD3MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809353-B2 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | disclosed |
| US-8158637-B2 | Sodium channel moderators; antiarrhythmia agents; analgesics; antiarthritic agents; antiinflammatory agents; antieplipetic agents; psychological disorders; nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1957482-B1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMA (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7928107-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-17 | — | — | US | disclosed |
| EP-1784393-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080221137-A1 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-09-11 | — | — | US | disclosed |
| EP-1957482-A2 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | Vertex Pharmaceuticals, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080167305-A1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| WO-2007058989-A2 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-1784393-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | CHEK2 2935/4885SMAD3 4194/4885MEN1 2548/4885 |
| US-20080167305-A1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | KCNQ1, KCNQ2, KCNQ5 | CHEK2 3091/4885SMAD3 4191/4885MEN1 3006/4885 |
| US-20080221137-A1 | Quinazolines useful as modulators of voltage gated ion channels | KCNQ1, KCNQ2, KCNQ5 | CHEK2 3091/4885SMAD3 4191/4885MEN1 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.